MRNA Network: Solution for Tracking Chemotherapy Insensitivity in Small-Cell Lung Cancer

Overview

Journal J Healthc Eng

Specialty Biomedical Engineering

Date 2021 Oct 8

PMID 34621500

Citations 3

Authors

Peixin Chen

Shengyu Wu

Jia Yu

Xuzhen Tang

Chunlei Dai

Hui Qi

Junjie Zhu

Wei Li

Bin Chen

Jun Zhu

Hao Wang

Sha Zhao

Hongcheng Liu

Peng Kuang

Yayi He

Affiliations

Soon will be listed here.

Abstract

Background: Small-cell lung cancer (SCLC) has poor prognosis and is prone to drug resistance. It is necessary to search for possible influencing factors for SCLC chemotherapy insensitivity. Therefore, we proposed an mRNA network to track the chemotherapy insensitivity in SCLC.

Methods: Six samples of patients with SCLC were recruited for RNA sequencing. TopHat2 and Cufflinks were used to make differential analysis. Functional analysis was applied as well. Finally, multidimensional validation was applied for verifying the results we obtained by experiment.

Results: This study was a trial of drug resistance in 6 SCLC patients after first-line chemotherapy. The top 10 downregulated genes differentially expressed in the chemo-insensitive group were SERPING1, DRD5, PARVG, PRAME, NKX1-1, MCTP2, PID1, PLEKHA4, SPP1, and SLN. Cell-cell signaling by Wnt (=6.98 - 21) was the most significantly enriched GO term in biological process, while systemic lupus erythematosus (=6.97 - 10), alcoholism (=1.01 - 09), and transcriptional misregulation in cancer (=0.00227988) were the top three ones of KEGG pathways. In multiple public databases, we also highlighted and verified the vital role of glycolysis/gluconeogenesis pathway and corresponding genes in chemo-insensitivity in SCLC.

Conclusion: Our study confirmed some SCLC chemotherapy insensitivity-related genes, biological processes, and pathways, thus constructing the chemotherapy-insensitive network for SCLC.

Citing Articles

Retracted: mRNA Network: Solution for Tracking Chemotherapy Insensitivity in Small-Cell Lung Cancer.

Healthcare Engineering J J Healthc Eng. 2023; 2023:9858925.

PMID: 37946896 PMC: 10631982. DOI: 10.1155/2023/9858925.

[Lactate-induced up-regulation of PLEKHA4 promotes proliferation and apoptosis of human glioma cells].

Ye J, Xu W, Xi B, Wang N, Chen T Nan Fang Yi Ke Da Xue Xue Bao. 2023; 43(7):1071-1080.

PMID: 37488789 PMC: 10366507. DOI: 10.12122/j.issn.1673-4254.2023.07.03.

Characterization of Fatty Acid Metabolism in Lung Adenocarcinoma.

Wang S, Chen A, Zhu W, Feng D, Wei J, Li Q Front Genet. 2022; 13:905508.

PMID: 35910199 PMC: 9329533. DOI: 10.3389/fgene.2022.905508.

References

Eckardt J, von Pawel J, Pujol J, Papai Z, Quoix E, Ardizzoni A . Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol. 2007; 25(15):2086-92. DOI: 10.1200/JCO.2006.08.3998. View

Berns K, Berns A . Awakening of "Schlafen11" to Tackle Chemotherapy Resistance in SCLC. Cancer Cell. 2017; 31(2):169-171. DOI: 10.1016/j.ccell.2017.01.013. View

Huang Q, Wei H, Wu Z, Li L, Yao L, Sun Z . Preferentially Expressed Antigen of Melanoma Prevents Lung Cancer Metastasis. PLoS One. 2016; 11(7):e0149640. PMC: 4938541. DOI: 10.1371/journal.pone.0149640. View

Tay R, Fernandez-Gutierrez F, Foy V, Burns K, Pierce J, Morris K . Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial. Ann Oncol. 2019; 30(7):1114-1120. PMC: 6637373. DOI: 10.1093/annonc/mdz122. View

Van Den Borg R, Leonetti A, Tiseo M, Giovannetti E, Peters G . Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine. Expert Rev Anticancer Ther. 2019; 19(6):461-471. DOI: 10.1080/14737140.2019.1624530. View

Ogata H, Goto S, Sato K, Fujibuchi W, Bono H, Kanehisa M . KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 1998; 27(1):29-34. PMC: 148090. DOI: 10.1093/nar/27.1.29. View

Okamoto H, Watanabe K, Kunikane H, Yokoyama A, Kudoh S, Asakawa T . Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer. 2007; 97(2):162-9. PMC: 2360311. DOI: 10.1038/sj.bjc.6603810. View

Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg S . TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 2013; 14(4):R36. PMC: 4053844. DOI: 10.1186/gb-2013-14-4-r36. View

Feng M, Xiong G, Cao Z, Yang G, Zheng S, Qiu J . LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer. J Exp Clin Cancer Res. 2018; 37(1):274. PMC: 6233565. DOI: 10.1186/s13046-018-0947-4. View

10.

Ghandi M, Huang F, Jane-Valbuena J, Kryukov G, Lo C, McDonald 3rd E . Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. 2019; 569(7757):503-508. PMC: 6697103. DOI: 10.1038/s41586-019-1186-3. View

11.

Xu M, Chen S, Yang W, Cheng X, Ye Y, Mao J . FGFR4 Links Glucose Metabolism and Chemotherapy Resistance in Breast Cancer. Cell Physiol Biochem. 2018; 47(1):151-160. DOI: 10.1159/000489759. View

12.

Kim E . Chemotherapy Resistance in Lung Cancer. Adv Exp Med Biol. 2015; 893:189-209. DOI: 10.1007/978-3-319-24223-1_10. View

13.

Banerjee A, Arvinrad P, Darley M, Laversin S, Parker R, Rose-Zerilli M . The effects of restricted glycolysis on stem-cell like characteristics of breast cancer cells. Oncotarget. 2018; 9(33):23274-23288. PMC: 5955399. DOI: 10.18632/oncotarget.25299. View

14.

Su L, Cui S, Zhen H, Liu J . Quantitative proteomic study of mitoxantrone-resistant NCI-H460 cell-xenograft tumors. Int J Clin Exp Pathol. 2020; 11(5):2377-2388. PMC: 6958271. View

15.

Owonikoko T, Dahlberg S, Sica G, Wagner L, Wade 3rd J, Srkalovic G . Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study. J Clin Oncol. 2018; 37(3):222-229. PMC: 6338394. DOI: 10.1200/JCO.18.00264. View

16.

Uhlen M, Fagerberg L, Hallstrom B, Lindskog C, Oksvold P, Mardinoglu A . Proteomics. Tissue-based map of the human proteome. Science. 2015; 347(6220):1260419. DOI: 10.1126/science.1260419. View

17.

von Mering C, Huynen M, Jaeggi D, Schmidt S, Bork P, Snel B . STRING: a database of predicted functional associations between proteins. Nucleic Acids Res. 2003; 31(1):258-61. PMC: 165481. DOI: 10.1093/nar/gkg034. View

18.

Misumi Y, Okamoto H, Sasaki J, Masuda N, Ishii M, Shimokawa T . Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604. BMC Cancer. 2017; 17(1):377. PMC: 5446686. DOI: 10.1186/s12885-017-3353-y. View

19.

Tang H, Chen J, Han X, Feng Y, Wang F . Upregulation of Is a Marker for Poor Lung Cancer Prognosis and Contributes to Cancer Progression and Cisplatin Resistance. Front Cell Dev Biol. 2021; 9:646390. PMC: 8116663. DOI: 10.3389/fcell.2021.646390. View

20.

Canitrot Y, Bichat F, Cole S, Deeley R, Gerlach J, Bastian G . Multidrug resistance genes (MRP) and MDR1 expression in small cell lung cancer xenografts: relationship with response to chemotherapy. Cancer Lett. 1998; 130(1-2):133-41. DOI: 10.1016/s0304-3835(98)00128-1. View